SSGA – Uncommon Sense

Good Afternoon,

Attached is the most recent “Uncommon Sense” piece put together by Michael Arone at SSGA. The theme is the recent increase in volatility, and he discusses the following three points:

1.) Investors have relied on the “Fed Put” during the market run-up, and he believes this remains in play with the new Fed Chair, Powell

2.) We are still in a Goldilocks market environment, with modest “not too hot, not too cold” growth

3.) Fundamentals continue to be the driver of growth in the stock market, and the numbers continue to be solid

As always, we want to temper client expectations and reactions in the short term but it is notable that, since the market correction earlier this month, global equity markets have already begun to rebound while volatility has fallen.

Below are a few charts from the piece worth sharing:

Uncertainty Caused by new Fed Chair – the Fed “Put” (ability of the Fed to reduce Fed funds rate when markets sell off)

Stock market pullbacks following new Fed Chair are not uncommon

Stock market pullbacks (in general) are relatively common but we had not seen a correction in over two years

Peter Malone, CFA

Research Analyst

Direct: 617.226.0030

Fax: 617.523.8118

Crestwood Advisors

One Liberty Square

Suite 500

Boston, MA 02109

www.crestwoodadvisors.com

PLEASE NOTE!

We moved! Please note our new location above!

Uncommon Sense – February 2018.pdf

DBLTX – Q4 2017 Commentary

DBLTX – Q4 2017 Commentary

The DoubleLine Total Return Bond Fund lagged the Barclays Agg during the fourth quarter but outperformed for the year in 2017. Gundlach and team continue to favor securitized assets and believe U.S. economic growth should continue through the next year.

I have attached the DoubleLine broad fixed income sector commentary as a reference. This includes a lot of good information across all of fixed income.

Market Overview:

– It was another strong quarter for risk assets to close out the year

o Synchronized expansion in global economic activity across both emerging and developed markets continued to provide widespread gains across a variety of asset classes

– Reduced level of volatility across U.S. markets was driven largely by continued QE, quantitative easing, accommodative fiscal policy, strong consumer sentiment

– 10 Year UST yields moved slightly lower for the year and the Fed hiked three times

o When the 10 year UST yield began testing the lower end of the range in Q3, Gundlach turned openly bearish on the 10 year given expectations of rising rates

o 10 year hit 2.04 in September and ended the year up almost 40 bps ahead at 2.40%

– Big news during the fourth quarter was the approval of the new tax plan in the U.S.

o Corporate tax rate reduction had positive impact on equity markets

o Time will tell what the long term economic impact will be

– Fed raised rates in December for the third time of 2017

o First time since financial crisis that the Fed followed through on its promise of expected rate hikes

Performance Overview:

– In the fourth quarter, DBLTX underperformed the Agg by 39 bps

– While all sectors contributed positively to performance, the sell-off in the UST curve impacted valuations across fixed income

– Prices were down across Agency RMBS with longer duration derivative positions

o Inverse floating rate and inverse interest-only securities were worst performers

– Pass-throughs were the best performing in this sector as these investments generated positive total return due to interest income

o Non-agency RMBS contributed positively to performance due to strong interest income

– Subprime securities outperformed as prices increased during the quarter

– Amongst other securitized credit sectors, returns were positive due to interest income

– While prices were down on ABS and CMBS, CLOs

Market Outlook:

– Growth expectations and economic data remains strong in the U.S.

o Unemployment rate held steady at 4.1% which is a 17 year low

– Along with the ongoing downtrend in unemployment, consumer confidence remains strong

o The Conference Board’s Consumer Confidence Index rose to 122.1

– This level is higher than pre-global financial crisis and is indicative of strong consumer sentiment

– The ISM Non-Manufacturing Index dropped to 55.9 from 57.4

o Index level above 50 signals expansion across the respective sectors

– All of this points to an economy that still has room to grow

– On a macro level, Gundlach believes that equities are likely to pull back over the next year and he is skeptical about credit

o Does not believe there is reason to expect a recession and likes commodities as a general asset class

Performance Review:

Peter Malone, CFA

Research Analyst

Direct: 617.226.0030

Fax: 617.523.8118

Crestwood Advisors

50 Federal Street, Suite 810

Boston, MA 02110

www.crestwoodadvisors.com

PLEASE NOTE!

On February 26 Crestwood will move to our new located at:

One Liberty Square

Suite 500

Boston, MA 02109

DoubleLine Commentary Q4 2017.pdf

Medtronic reported solid 3Q FY18 earnings but delay in robotics program weigh on the stock today

Medtronic reported strong 3Q FY18 sales and earnings results this morning. FY18 guidance and FY19 commentary were reiterated. Competition is still a threat to MDT’s growth, but we expect some tuck-in M&A to help, following the cash repatriation from the tax reform. Price target increased to $93.

Continue reading “Medtronic reported solid 3Q FY18 earnings but delay in robotics program weigh on the stock today”

Pepsi 4Q17 earnings: results in line, 2018 guidance is conservative

Pepsi reported 4Q17 earnings in line with estimates of organic sales +2.3% and EPS growth of +8%. Management provided its initial 2018 guidance which is a bit light vs. expectations, but certainly achievable for Pepsi. We will look for a positive margin progression in the coming quarters as new products come to the market. Currently the stock is supported by an increased dividend and new repurchase program. Price target unchanged at this time. Continue reading “Pepsi 4Q17 earnings: results in line, 2018 guidance is conservative”

Fortive 4Q17 earnings results were good – 2018 guidance is supportive of our thesis

Fortive reported a good 4Q17 with sales growth of 11% (+3% organic) and adjusted EPS growth of 20.6%, mostly in line with expectations. Management provided its initial 2018 guidance of 3-4% organic sales growth and 16-19% EPS growth. We should expect some M&A activity during the year, with $5B available for deals. We are pleased with the results and maintain our position size and price target. Continue reading “Fortive 4Q17 earnings results were good – 2018 guidance is supportive of our thesis”

CVS 4Q17 earnings were good, but 2018 profit guidance lowered as the company reinvests in the business

CVS reported 4Q17 revenue growth of 5.3%, and adjusted EPS of $1.92 (+12% y/y) at the high end of its guidance. CVS provided its 2018 guidance which was good, although expected profit was lowered by 250bps to account for the $275M reinvestments that will be made in the business (wages/benefits, data analytics and new store format). We are not surprised by this disclosure as it was our assumptions that extra cash from the tax reform would be put into the business. We remain bullish on the company’s strategy and are maintaining our position size and price target. Continue reading “CVS 4Q17 earnings were good, but 2018 profit guidance lowered as the company reinvests in the business”

TORIX – Q4 2017 Market Commentary

TORIX – Q4 2017 Market Commentary

The Tortoise MLP and Pipeline Fund outpaced its North American Pipeline Index during the fourth quarter, and the broad energy sector began to turn around. Despite a year of underperformance for the MLP space, Tortoise believes that midstream company fundamentals remain strong and a growth opportunity remains as the need for greater pipeline capacity has ramped up.

Continue reading “TORIX – Q4 2017 Market Commentary”

Sanofi reported disappointing sales and EPS growth in 4Q17, recent deals integration will be key

Sanofi reported 4Q17 sales growth of -1.6%, impacted by the Dengue vaccine issue in the Philippine and continued pressure in its Diabetes franchise in the US. As a consequence, Business EPS declined ~9%. Sanofi has been more successful recently in its M&A strategy, which should bring back some growth to the business in the coming years. Price target and position size unchanged. Continue reading “Sanofi reported disappointing sales and EPS growth in 4Q17, recent deals integration will be key”